Clinical Trial Update: A Study On Concentrations Of 16448 In Blood And The Safety Of This Compound In Healthy Males With Premature Ejaculation [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating blood concentrations and safety of the compound 16448 in healthy male volunteers with premature ejaculation; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premature Ejaculation

Drugs mentioned

• 16448

Snippet

Sponsor: GlaxoSmithKline | Conditions: Premature Ejaculation | Phase 2 | Status: COMPLETED